Cited by 4,347Dementia and Cognitive Impairment ResearchAdvanced MRI Techniques and ApplicationsMedical Imaging Techniques and Applications

The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods

Open access
Jack, Clifford R., Bernstein, Matt A., Fox, Nick C., Thompson, Paul, Alexander, Gene, Harvey, Danielle, Borowski, Bret, Britson, Paula J. +27 more·2008·Journal of Magnetic Resonance Imaging

Abstract

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a longitudinal multisite observational study of healthy elders, mild cognitive impairment (MCI), and Alzheimer's disease. Magnetic resonance imaging (MRI), (18F)-fluorodeoxyglucose positron emission tomography (FDG PET), urine serum, and cerebrospinal fluid (CSF) biomarkers, as well as clinical/psychometric assessments are acquired at multiple time points. All data will be cross-linked and made available to the general scientific community. The purpose of this report is to describe the MRI methods employed in ADNI. The ADNI MRI core established specifications that guided protocol development. A major effort was devoted to evaluating 3D T(1)-weighted sequences for morphometric analyses. Several options for this sequence were optimized for the relevant manufacturer platforms and then compared in a reduced-scale clinical trial. The protocol selected for the ADNI study includes: back-to-back 3D magnetization prepared rapid gradient echo (MP-RAGE) scans; B(1)-calibration scans when applicable; and an axial proton density-T(2) dual contrast (i.e., echo) fast spin echo/turbo spin echo (FSE/TSE) for pathology detection. ADNI MRI methods seek to maximize scientific utility while minimizing the burden placed on participants. The approach taken in ADNI to standardization across sites and platforms of the MRI protocol, postacquisition corrections, and phantom-based monitoring of all scanners could be used as a model for other multisite trials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jmri.21049

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The ADNI dataset contains MRI longitudinal image scans in AD patients from 63 sites across the US and Canada.

    “The ADNI dataset as one example in brain datasets contains MRI longitudinal image scans in AD patients from 63 sites across the US and Canada.”

    From A review of deep learning-based deformable medical image registration (2022) · cites this paper as [26]

    The Abstract describes longitudinal MRI scans of participants with Alzheimer’s disease at multiple North American sites. It specifies 55 participating sites, however, not the claimed 63, and does not explicitly identify the countries as the US and Canada. (LLM, conf=0.90)

    Experimental — accuracy not yet measured
  • ADNI develops standardized protocols for multi-center comparison and has helped over 1,000 scientific publications explore prevention and treatment of AD since 2004.

    “ADNI develops standardized protocols for multi-center comparison and helps over 1,000 scientific publications explore the prevention and treatment of AD since 2004”

    From A review of deep learning-based deformable medical image registration (2022) · cites this paper as [26]

    The Abstract and Discussion (page numbers unavailable) describe ADNI’s development of standardized MRI methods for multisite studies. The Results mention a protocol-selection meeting in 2004, but our copy does not substantiate the claim that ADNI helped over 1,000 publications explore AD prevention and treatment since then. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • ADNI is the largest and most influential benchmark for Alzheimer's Disease research, including ADNI-1, ADNI-2, ADNI-GO and ADNI-3.

    “ADNI-The Alzheimer's Disease Neuroimaging Initiative (ADNI) [101,102] is the largest and most influential benchmark for the research of Alzheimer's Disease (AD), including ADNI-1, ADNI-2, ADNI-GO and ADNI-3.”

    From Federated learning for medical image analysis: A survey (2024) · cites this paper as [102]

  • ADNI provides structural brain MRI, functional MRI, and PET from 1900+ subjects and 59 centers.

    “Structural brain MRI, functional MRI, and positron emission tomography (PET) from 1900+ subjects and 59 centers are provided for analysis and research.”

    From Federated learning for medical image analysis: A survey (2024) · cites this paper as [102]

  • The ADNI dataset used in the experiment comprises ADNI-1 with 1.5T T1-weighted MRIs from 428 subjects (199 AD, 229 NC) and ADNI-2 with 3.0T T1-weighted MRIs from 360 subjects (159 AD, 201 NC).

    “This dataset comprises two subsets: ADNI-1, featuring 1.5T T1-weighted MRIs from 428 subjects (199 with Alzheimer's Disease (AD) and 229 normal controls (NCs)), and ADNI-2, with 3.0T T1weighted MRIs from 360 subjects (159 AD patients and 201 NCs).”

    From Federated learning for medical image analysis: A survey (2024) · cites this paper as [102]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Dickerson BC, Goncharova I, Sullivan MP, et al. MRI-derived ento- rhinal and hippocampal atrophy in incipient and very mild Alzhei- mer's disease. Neurobiol Aging 2001;22:747-754.

Cited by

Sorted by citations

Authors
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., Dale, A. M., Felmlee, J. P., Gunter, J. L., Hill, D. L. G., Killiany, R., Schuff, N., Fox‐Bosetti, S., Lin, C., Studholme, C., DeCarli, C. S., Krueger, G., Ward, H. A., Metzger, G. J., Scott, K. T., Mallozzi, R., Blezek, D., Levy, J., Debbins, J. P., Fleisher, A. S., Albert, M., Green, R., Bartzokis, G., Glover, G., Mugler, J., & Weiner, M. W.
Affiliations
  • Mayo Clinic (US)
  • National Hospital for Neurology and Neurosurgery (GB)
  • University of California, Los Angeles (US)
  • Arizona State University (US)
  • University of California, Davis (US)
  • University of California San Diego (US)
  • San Francisco VA Medical Center (US)
  • Philips (Netherlands) (NL)
  • General Electric (United States) (US)
  • Johns Hopkins University (US)
  • Boston University (US)
  • Stanford Medicine (US)
  • University of Virginia (US)
Corresponding author
Jack, Clifford R.
Venue
Journal of Magnetic Resonance Imaging
Publisher
Wiley
Published
2008-02-26
Volume
27
Issue
4
Pages
685-691
ISSN
  • 1053-1807 (ISSN-L)
  • 1522-2586
OpenAlex
W2078524519
Cited by
4,347
References
21
Citations by year
2026: 298 · 2025: 359 · 2024: 292 · 2023: 291 · 2022: 266 · 2021: 319 · 2020: 336 · 2019: 256 · 2018: 223 · 2017: 193 · 2016: 255 · 2015: 264 · 2014: 233 · 2013: 217 · 2012: 165
FWCI
86.66
Type
journal article
Language
en
Open access
Locations
  • Journal of Magnetic Resonance Imaging (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
  • Foundation for the National Institutes of Health (U01AG024904, AG024904)
  • Alzheimer's Association (U01 AG024904)
  • Bristol-Myers Squibb (U01 AG024904, AG024904)
  • Eli Lilly and Company (U01 AG024904, AG024904)
  • Pfizer (AG024904, U01 AG024904)
  • AstraZeneca
  • GlaxoSmithKline
  • Alzheimer's Disease Neuroimaging Initiative (U01AG024904, AG024904)
  • Novartis Pharmaceuticals Corporation (U01 AG024904, AG024904)
  • Elan (U01 AG024904)
  • Eisai (U01 AG024904, AG024904)
  • National Institutes of Health (5u01ag024904-10, U01-AG024904, AG024904)
  • U.S. Food and Drug Administration
  • National Institute on Aging (U01-AG-024904, P30AG010129, AG 024904, U19AG010483)
  • National Institute of Biomedical Imaging and Bioengineering (U01 AG024904, AG024904)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
Alzheimer's disease, mild cognitive impairment, MRI protocol standardization, 3D T1-weighted imaging, MPRAGE, fast spin echo, brain morphometry, longitudinal neuroimaging
MeSH terms
Aged, Alzheimer Disease, Brain, Humans, Magnetic Resonance Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review